PL3090748T3 - Kompozycje zawierające proleki nukleotydowe i oligonukleotydowe - Google Patents

Kompozycje zawierające proleki nukleotydowe i oligonukleotydowe

Info

Publication number
PL3090748T3
PL3090748T3 PL16158945T PL16158945T PL3090748T3 PL 3090748 T3 PL3090748 T3 PL 3090748T3 PL 16158945 T PL16158945 T PL 16158945T PL 16158945 T PL16158945 T PL 16158945T PL 3090748 T3 PL3090748 T3 PL 3090748T3
Authority
PL
Poland
Prior art keywords
nucleotide
compositions
oligonucleotide prodrugs
prodrugs
oligonucleotide
Prior art date
Application number
PL16158945T
Other languages
English (en)
Inventor
Radhakrishnan P. Iyer
Seetharamaiyer Padmanabhan
Original Assignee
Spring Bank Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spring Bank Pharmaceuticals, Inc. filed Critical Spring Bank Pharmaceuticals, Inc.
Publication of PL3090748T3 publication Critical patent/PL3090748T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
PL16158945T 2005-12-13 2006-12-13 Kompozycje zawierające proleki nukleotydowe i oligonukleotydowe PL3090748T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US75003605P 2005-12-13 2005-12-13
US80029406P 2006-05-15 2006-05-15
US11/637,520 US8076303B2 (en) 2005-12-13 2006-12-12 Nucleotide and oligonucleotide prodrugs
EP16158945.2A EP3090748B1 (en) 2005-12-13 2006-12-13 Compositions comprising nucleotide and oligonucleotide prodrugs
EP06848625.7A EP1968612B1 (en) 2005-12-13 2006-12-13 Dinucleotide prodrugs
PCT/US2006/047617 WO2007070598A2 (en) 2005-12-13 2006-12-13 Nucleotide and oligonucleotide prodrugs

Publications (1)

Publication Number Publication Date
PL3090748T3 true PL3090748T3 (pl) 2020-03-31

Family

ID=38194676

Family Applications (2)

Application Number Title Priority Date Filing Date
PL06848625.7T PL1968612T3 (pl) 2005-12-13 2006-12-13 Proleki dinukleotydowe
PL16158945T PL3090748T3 (pl) 2005-12-13 2006-12-13 Kompozycje zawierające proleki nukleotydowe i oligonukleotydowe

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL06848625.7T PL1968612T3 (pl) 2005-12-13 2006-12-13 Proleki dinukleotydowe

Country Status (17)

Country Link
US (6) US8076303B2 (pl)
EP (3) EP3553072A1 (pl)
JP (1) JP5044854B2 (pl)
KR (2) KR101123534B1 (pl)
CN (2) CN102796155B (pl)
CY (2) CY1117576T1 (pl)
DK (2) DK3090748T3 (pl)
ES (2) ES2573928T3 (pl)
HR (1) HRP20160531T1 (pl)
HU (2) HUE044034T2 (pl)
IN (1) IN2015DN01786A (pl)
LT (1) LT3090748T (pl)
PL (2) PL1968612T3 (pl)
PT (1) PT3090748T (pl)
RS (1) RS54867B1 (pl)
SI (2) SI3090748T1 (pl)
WO (1) WO2007070598A2 (pl)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2434906C (en) * 2001-01-16 2008-08-19 Can-Fite Biopharma Ltd. Use of an adenosine a3 receptor agonist for inhibition of viral replication
US8076303B2 (en) * 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
KR101806314B1 (ko) * 2008-04-03 2017-12-07 스프링 뱅크 파마슈티칼스, 인크. 바이러스 감염증을 치료하기 위한 조성물 및 방법
WO2010039543A2 (en) * 2008-09-23 2010-04-08 Traversa Therapeutics, Inc. Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference
BRPI0923225A2 (pt) 2008-12-02 2016-10-04 Chiralgen Ltd metodo para sintese de acidos nucleicos modificados no atomo de fosforo
CN102307889A (zh) * 2008-12-23 2012-01-04 集润德斯股份公司 硫化剂及其用于寡核苷酸合成的用途
EP2451461A4 (en) 2009-07-06 2013-05-29 Ontorii Inc NOVEL NUCLEIC ACID PRODRUGS AND METHOD OF USE THEREOF
AU2015255202B2 (en) * 2009-07-06 2017-07-27 Wave Life Sciences Ltd. Novel nucleic acid prodrugs and methods of use thereof
CN101659612B (zh) * 2009-09-24 2013-01-09 华润赛科药业有限责任公司 一种选择性酯化的方法
US9040234B2 (en) * 2010-08-30 2015-05-26 Spring Bank Pharmaceuticals, Inc. Oligonucleotide analogs as therapeutic agents
DK2620428T3 (da) 2010-09-24 2019-07-01 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
CN107365339A (zh) 2011-07-19 2017-11-21 波涛生命科学有限公司 合成官能化核酸的方法
KR101327026B1 (ko) 2011-11-29 2013-11-13 현대자동차주식회사 운전자 보호장치
DK2872147T3 (da) * 2012-07-13 2023-02-20 Wave Life Sciences Ltd Fremgangsmåde til fremstilling af kirale oligonukleotider
SG11201500243WA (en) 2012-07-13 2015-04-29 Shin Nippon Biomedical Lab Ltd Chiral nucleic acid adjuvant
WO2014010250A1 (en) 2012-07-13 2014-01-16 Chiralgen, Ltd. Asymmetric auxiliary group
CN105992587A (zh) * 2013-02-18 2016-10-05 春堤制药公司 作为疫苗佐剂和治疗试剂的短寡核苷酸的设计
EP3095459A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
WO2015108046A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
EP3095461A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
EP3094728B1 (en) 2014-01-16 2022-03-09 Wave Life Sciences Ltd. Chiral design
GB201403697D0 (en) * 2014-03-03 2014-04-16 Link Technologies Ltd Compounds and methods of use
CN106794188B (zh) 2014-09-28 2022-12-02 华辉安健（北京）生物科技有限公司 聚合胆汁酸衍生物抑制乙型肝炎病毒和丁型肝炎病毒和ntcp运输
US20190046552A1 (en) * 2015-04-07 2019-02-14 Spring Bank Pharmaceuticals, Inc. Compositions and methods for the treatment of hcv infection
CA2991156A1 (en) * 2015-07-02 2017-01-05 Spring Bank Pharmaceuticals, Inc. Compositions and methods for the treatment of viral infection
US20190070212A1 (en) * 2016-03-11 2019-03-07 Spring Bank Pharmaceuticals, Inc. Compounds and compositions for the treatment of infections
SG11201900154VA (en) * 2016-07-15 2019-02-27 Sperovie Biosciences Inc Compounds, compositions, and methods for the treatment of disease
WO2018100558A2 (en) * 2016-12-01 2018-06-07 Takeda Pharmaceutical Company Limited Cyclic dinucleotide
US20200055883A1 (en) 2017-02-17 2020-02-20 Eisai R&D Management Co., Ltd. Cyclic di-nucleotides derivative for the treatment of cancer
AR113224A1 (es) 2017-04-28 2020-02-19 Novartis Ag Conjugados de anticuerpo que comprenden un agonista de sting
US11707531B2 (en) * 2017-09-11 2023-07-25 F-star Therapeutics, Inc. Compounds, compositions, and methods for the treatment of disease
WO2019051488A1 (en) 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE
CN110467647B (zh) * 2018-05-09 2022-08-30 博瑞生物医药（苏州）股份有限公司 双核苷酸前体药物的制备方法
CN110467646A (zh) * 2018-05-09 2019-11-19 博瑞生物医药（苏州）股份有限公司 双核苷酸前体药物
WO2019219070A1 (zh) * 2018-05-18 2019-11-21 正大天晴药业集团股份有限公司 氘代的低聚核苷酸及前体药物
US12251394B2 (en) 2018-06-01 2025-03-18 Eisai R&D Management Co., Ltd. Methods for the treatment of bladder cancer
FR3082434B1 (fr) 2018-06-14 2021-04-30 Cairdac Implant cardiaque autonome de type "capsule leadless", comprenant un recuperateur d'energie a lame piezoelectrique
KR102783784B1 (ko) 2018-08-16 2025-03-21 에자이 알앤드디 매니지먼트 가부시키가이샤 화합물의 염 및 이의 결정
CN113348181A (zh) 2018-10-31 2021-09-03 诺华股份有限公司 包含sting激动剂的dc-sign抗体缀合物
WO2020089815A1 (en) 2018-10-31 2020-05-07 Novartis Ag Antibody conjugates comprising sting agonist
WO2020114495A1 (zh) * 2018-12-06 2020-06-11 正大天晴药业集团股份有限公司 二核苷酸化合物及其前体药物
CN111484541B (zh) * 2019-01-25 2023-06-02 博瑞生物医药（苏州）股份有限公司 双核苷酸前体药物及其制备方法
CN111484540B (zh) * 2019-01-25 2023-09-08 博瑞生物医药（苏州）股份有限公司 含双核苷酸结构的化合物

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US688183A (en) 1900-12-17 1901-12-03 Carl C Lantz Adjusting-clip for garment-supporters.
DE2817041C2 (de) 1978-04-19 1987-02-19 Reich Spezialmaschinen GmbH, 7440 Nürtingen Vorrichtung zum Aufteilen von Platten
CS264222B1 (en) * 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
WO1991016327A1 (en) 1990-04-18 1991-10-31 Norwich Eaton Pharmaceuticals, Inc. Antimicrobial quinolonyl lactams
US5444063A (en) 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5432165A (en) 1992-04-06 1995-07-11 Oclassen Pharmaceuticals, Inc. Methods for the treatment of infection caused by Hepatitis B virus (HBV)
US5955591A (en) * 1993-05-12 1999-09-21 Imbach; Jean-Louis Phosphotriester oligonucleotides, amidites and method of preparation
FR2705099B1 (fr) 1993-05-12 1995-08-04 Centre Nat Rech Scient Oligonucléotides phosphorothioates triesters et procédé de préparation.
FR2709754B1 (fr) 1993-09-10 1995-12-01 Centre Nat Rech Scient Composés 2' ou 3'-déoxy- et 2', 3'-didéoxy-beta-L-pentofuranonucléosides, procédé de préparation et application thérapeutique, notamment anti-virale.
US5587362A (en) 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
US5581639A (en) 1995-05-04 1996-12-03 National Research Council Of Canada Raman-nath diffraction grating
WO1998007734A1 (en) 1996-08-21 1998-02-26 Hybridon, Inc. Oligonucleotide prodrugs
WO1998017281A1 (en) 1996-10-24 1998-04-30 Vion Pharmaceuticals, Inc. MONOPHOSPHATE PRODRUGS OF β-L-FD4C AND β-L-FddC AS POTENT ANTIVIRAL AGENTS
CA2599597A1 (en) 1998-08-10 2000-02-24 Idenix (Cayman) Limited .beta.-l-2'-deoxy-nucleosides for the treatment of hepatitis b
US6395716B1 (en) 1998-08-10 2002-05-28 Novirio Pharmaceuticals Limited β-L-2′-deoxy-nucleosides for the treatment of hepatitis B
US6444652B1 (en) 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
HRP20030047B1 (hr) 2000-07-21 2016-02-26 Gilead Sciences, Inc. Prolijekovi koji su fosfonatni analozi nukleotida i metode njihovog odabira te njihova priprava
WO2002092006A2 (en) * 2001-05-16 2002-11-21 Micrologix Biotech, Inc. Nucleic acid-based compounds and methods of use thereof
US8076303B2 (en) * 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
CN101146337B (zh) 2006-09-15 2011-04-20 华为技术有限公司 新接入节点随机接入的方法及其系统
KR101806314B1 (ko) * 2008-04-03 2017-12-07 스프링 뱅크 파마슈티칼스, 인크. 바이러스 감염증을 치료하기 위한 조성물 및 방법

Also Published As

Publication number Publication date
KR101248873B1 (ko) 2013-04-02
RS54867B1 (sr) 2016-10-31
ES2573928T3 (es) 2016-06-13
SI3090748T1 (sl) 2019-09-30
US10047114B2 (en) 2018-08-14
EP1968612B1 (en) 2016-03-09
EP3553072A1 (en) 2019-10-16
HUE044034T2 (hu) 2019-09-30
PT3090748T (pt) 2019-06-04
WO2007070598A9 (en) 2007-11-08
US20070149462A1 (en) 2007-06-28
DK1968612T3 (en) 2017-05-22
EP3090748B1 (en) 2019-02-20
WO2007070598A3 (en) 2008-10-30
CN102796155A (zh) 2012-11-28
EP1968612A4 (en) 2013-01-09
EP1968612A2 (en) 2008-09-17
US10344046B2 (en) 2019-07-09
PL1968612T3 (pl) 2016-11-30
SI1968612T1 (sl) 2016-10-28
JP2009519345A (ja) 2009-05-14
LT3090748T (lt) 2019-08-26
CY1117576T1 (el) 2017-04-26
CN101437397B (zh) 2012-09-05
WO2007070598A8 (en) 2008-12-31
US20180273574A1 (en) 2018-09-27
CN101437397A (zh) 2009-05-20
US8076303B2 (en) 2011-12-13
KR20080072084A (ko) 2008-08-05
HRP20160531T1 (hr) 2016-08-12
WO2007070598A2 (en) 2007-06-21
US20140323554A1 (en) 2014-10-30
US20160060287A1 (en) 2016-03-03
CY1121639T1 (el) 2020-07-31
KR20110125677A (ko) 2011-11-21
US20200087338A1 (en) 2020-03-19
US8691787B2 (en) 2014-04-08
US20120264709A1 (en) 2012-10-18
CN102796155B (zh) 2015-08-26
JP5044854B2 (ja) 2012-10-10
DK3090748T3 (da) 2019-05-27
EP3090748A1 (en) 2016-11-09
ES2729657T3 (es) 2019-11-05
KR101123534B1 (ko) 2012-03-13
HUE029190T2 (en) 2017-02-28
IN2015DN01786A (pl) 2015-07-10

Similar Documents

Publication Publication Date Title
SI3090748T1 (sl) Sestavki, ki vsebujejo nukleotidna in oligonukleotidna predzdravila
SG10201400978PA (en) Oligonucleotide analogues incorporating 5-aza-cytosine therein
IL178500A0 (en) Glucosamine and glucosamine/anti-inflammatory mutual prodrugs, compositions, and methods
EP1934837A4 (en) TARGETED ADVERTISING
EP1882392A4 (en) GENES AND THEIR USES FOR PLANT IMPROVEMENTS
ZA200902823B (en) Oligoribonucleotides and uses thereof
IL179438A0 (en) Levodopa prodrugs, and compositions and uses thereof
IL198947A0 (en) Composition comprising oligogalacturonans and polycationic saccharides
GB0613796D0 (en) Blower
EP1996730A4 (en) CLEANING OF SMALL RNA
ZA200800228B (en) Nucleotide analogue prodrug and the preparation thereof
IL199056A0 (en) Acetaminophen compositions having minimized side effects including reduced hepato-toxicity
GB0718409D0 (en) Formulations
GB0619182D0 (en) Oligonucleotide arrays
GB0514889D0 (en) Oligonucleotides
AP2008004705A0 (en) Pnem prodrugs
ZA200708936B (en) Catalyst compositions
GB0421294D0 (en) Bioreductively-activated prodrugs
GB0524012D0 (en) Multipurpose distribution matrix
GB0615609D0 (en) Uses and compositions comprising miRNAs
IL161579A0 (en) ANTISENSE OLIGONUCLEOTIDES AGAINST cPLA2, COMPOSITIONS AND USES THEREOF
GB0522578D0 (en) Ribozymal nucleic acid
GB0421296D0 (en) Bioreductively-activated prodrugs
GB0403424D0 (en) Ink compositions
GB0515699D0 (en) Prodrugs